NT 157Alternative Names: NT157
Latest Information Update: 27 Jan 2017
At a glance
- Originator Hebrew University of Jerusalem
- Developer TyrNovo
- Class Small molecules
- Mechanism of Action Insulin receptor substrate protein inhibitors; STAT3 transcription factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Malignant melanoma; Ovarian cancer; Prostate cancer
- Research Acute lymphoblastic leukaemia; Osteosarcoma